NASDAQ:YMAB - Y-mAbs Therapeutics Stock Price, Forecast & News

Y-mAbs Therapeutics trades on the NASDAQ under the ticker symbol "YMAB."

Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) announced its quarterly earnings results on Wednesday, November, 13th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by $0.16. View Y-mAbs Therapeutics' Earnings History.

Y-mAbs Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March 27th 2020. View Earnings Estimates for Y-mAbs Therapeutics.

5 brokerages have issued 1-year price targets for Y-mAbs Therapeutics' shares. Their forecasts range from $38.00 to $40.00. On average, they anticipate Y-mAbs Therapeutics' stock price to reach $39.25 in the next twelve months. This suggests a possible upside of 20.3% from the stock's current price. View Analyst Price Targets for Y-mAbs Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Y-mAbs Therapeutics.

News coverage about YMAB stock has been trending extremely negative recently, according to InfoTrie. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Y-mAbs Therapeutics earned a coverage optimism score of -5.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Y-mAbs Therapeutics.

Y-mAbs Therapeutics saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 1,650,000 shares, an increase of 55.7% from the December 15th total of 1,060,000 shares. Based on an average daily volume of 269,200 shares, the days-to-cover ratio is currently 6.1 days. Currently, 8.5% of the shares of the stock are sold short. View Y-mAbs Therapeutics' Current Options Chain.

Some companies that are related to Y-mAbs Therapeutics include BridgeBio Pharma (BBIO), Nektar Therapeutics (NKTR), United Therapeutics (UTHR), Allakos (ALLK), SAGE Therapeutics (SAGE), Blueprint Medicines (BPMC), HUTCHISON CHINA/S (HCM), Mirati Therapeutics (MRTX), Evotec (EVTCY), FibroGen (FGEN), Intercept Pharmaceuticals (ICPT), GW Pharmaceuticals PLC- (GWPH), Ultragenyx Pharmaceutical (RARE), Myokardia (MYOK) and Deciphera Pharmaceuticals (DCPH).

Based on aggregate information from My MarketBeat watchlists, some companies that other Y-mAbs Therapeutics investors own include Bank of Hawaii (BOH), InterDigital Wireless (IDCC), Stag Industrial (STAG), Corbus Pharmaceuticals (CRBP), Evoke Pharma (EVOK), JD.Com (JD), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Alibaba Group (BABA) and AVEO Pharmaceuticals (AVEO).

(YMAB) raised $80 million in an initial public offering (IPO) on Friday, September 21st 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager.

Shares of YMAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of YMAB stock can currently be purchased for approximately $32.62.

Y-mAbs Therapeutics has a market capitalization of $1.30 billion. The company earns $-43,270,000.00 in net income (profit) each year or ($1.50) on an earnings per share basis. Y-mAbs Therapeutics employs 32 workers across the globe.View Additional Information About Y-mAbs Therapeutics.

The official website for Y-mAbs Therapeutics is http://www.ymabs.com/.

Y-mAbs Therapeutics' mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The company can be reached via phone at 646-885-8505 or via email at [email protected]